Description
Riboxin Pharmacodynamics
Purine nucleoside, ATP precursor. It improves myocardial metabolism, has antihypoxic and antiarrhythmic effects. It increases myocardial energy balance. It has a protective effect on the kidneys in ischemia during surgery.
Participates in the metabolism of glucose, increases the activity of a number of enzymes of the Krebs cycle. Stimulates the synthesis of nucleotides.
Indications
CHD, myocardiodystrophy, conditions after myocardial infarction, congenital and acquired heart defects, heart rhythm disorders, especially in glycoside intoxication, myocarditis, myocardial degeneration after heavy physical exertion and infectious diseases, or due to endocrine disorders; hepatitis, liver cirrhosis, fatty liver dystrophy, including those caused by alcohol or drugs. Including those caused by alcohol or medications; prophylaxis of leukopenia during radioactive irradiation; isolated kidney surgery (as a means of pharmacological protection in the temporary absence of blood circulation in the operated organ).
Contraindications
Gout, hyperuricemia, hypersensitivity to inosin.
Dosage and administration
- If administered orally the initial daily dose is 600-800 mg, the dose is gradually increased to 2.4 g/ 3-4 doses.
- When administered intravenously (by trickle or drop), the initial dose is 200 mg 1 time/, then the dose is increased to 400 mg 1 to 2 doses.
- The duration of the course of treatment is set individually.
